Innovent Biologics

Innovent Biologics will present research findings at the 34th EADV Congress, showcasing data on IBI112 (picankibart) and preclinical results for IBI3013 and IAR129 via ePosters. Presentations include post-hoc analyses from Phase 2 and 3 trials of picankibart in psoriasis patients, focusing on efficacy in specific areas like the scalp and genitals, as well as comparisons between biologic-experienced and naive patients. Data on IBI3013, targeting IL-15, and IAR129, a bispecific antibody targeting IL-4R/OX40L for atopic dermatitis, will also be presented.

Innovent Biologics presented positive Phase 2 results for tigulixostat (IBI128), a xanthine oxidase inhibitor for gout, at APLAR 2025. The study (NCT06501534) in Chinese patients showed tigulixostat significantly reduced serum uric acid levels compared to febuxostat, with a favorable safety profile and no serious adverse events. Innovent plans to initiate Phase 3 trials in China in the second half of 2025, aiming to address the unmet need for safer and more effective gout treatments amidst concerns about existing therapies.

Innovent Biologics will present at the ADA’s 85th Scientific Sessions, unveiling research on its pipeline for metabolic disease. Key highlights include IBI3030, a novel anti-PCSK9 antibody conjugate, and promising results on mazdutide, a dual GCG/GLP-1 receptor agonist. Mazdutide data will focus on liver fat reduction, MASH and fibrosis improvement, and uric acid reduction. The presentation will feature results from preclinical studies and investigator-initiated trials, pointing to Innovent’s focus on innovative metabolic disease therapies.